Viewing Study NCT01499667

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:40 AM
Ignite Modification Date: 2026-05-24 @ 7:51 AM
Study NCT ID: NCT01499667
Status: TERMINATED
Last Update Posted: 2014-08-08
First Post: 2011-08-18
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsing Remitting Multiple Sclerosis (RRMS) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Relapsing remitting multiple sclerosis View
None multiple sclerosis (MS) View
None safety View
None tolerability View
None health outcomes View
None fingolimod View
None disease control View
None MRI View